Tech Company Financing Transactions
Rebiotix Funding Round
On 8/5/2014, Rebiotix secured $25 million in Series B financing from private investors.
Transaction Overview
Company Name
Announced On
8/5/2014
Transaction Type
Venture Equity
Amount
$25,000,000
Round
Series B
Investors
Proceeds Purpose
Rebiotix will use the additional funds to support pivotal clinical research to advance lead product RBX2660 (microbiota suspension) towards commercialization; for research and development on next-generation therapeutic products; for potential new treatment indications; and for general working capital.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
2660 Patton Rd.
Roseville, MN 55113
USA
Roseville, MN 55113
USA
Phone
Website
Email Address
Overview
Rebiotix Inc. is a biotechnology company founded in 2011 in Roseville, MN to revolutionize the treatment of challenging gastrointestinal diseases by harnessing the power of the human microbiome.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Michael Berman
Chief Executive Officer
Lee Jones
Chief Medical Officer
Dale Gerding
Chief Scientific Officer
Ken Blount
Founder
Erwin Kelen
VP - Finance
Nancy Timm
VP - Regulatory Affairs
Edward Burd
Browse more venture capital transactions:
Prev: 8/5/2014: Juno Therapeutics venture capital transaction
Next: 8/5/2014: Bitglass venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on funding rounds that are announced publicly. All VC database entries reported here are derived from company press releases and news coverage. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs